Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastroenterology
•
Allergy & Immunology
•
Mast Cell Disorders
•
Gastrointestinal Functional & Motility Disorders
•
General Gastroenterology
How do you counsel a patient on returning to the care of their PCP when a workup for MCAS has been unrevealing, but the patient insists that they have a mast cell disorder because they respond to antihistamine therapy?
Related Questions
Do you favor 24 hour urinary metabolites over random urine collection when screening for MCAS?
Is there a role for nitazoxanide for treatment of norovirus gastroenteritis in immunocompromised patients?
Are you requiring markers other than LTE4 to be elevated to diagnose MCAS?
What aspects of a patients clinical presentation would make you consider a diagnostic challenge of anakinra to assess for an underlying auto-inflammatory syndrome in hospitalized patient with fever of unknown origin?
Has your institution and/or antimicrobial stewardship program incorporated a selective antibiotic approach to treatment of left-sided uncomplicated diverticulitis in immunocompetent patients?
Do you usually recommend a modified diet for Clostridioides difficile infection (CDI)?
Is there a role for use of dupilumab for hypereosinophilic GI disorders distal to the esophagus?
What is your approach to treatment of patients with fulminant C difficile infection who required ileostomy creation or colectomy?
Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?
How do you approach managing nausea and GI side effects when initiating methotrexate?
